Claudins in ovarian cancer: emerging biomarkers and therapeutic targets

<p dir="ltr">Tight junctions (TJ) comprise protein complexes that help with the movement of ions and molecules through the paracellular pathway, thus maintaining both epithelial and endothelial integrity. The TJ proteins are diverse and include claudins, occludins, tricellulins, cing...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Lubna Therachiyil (4246156) (author)
مؤلفون آخرون: Ajaz A. Bhat (12984701) (author), Shahab Uddin (154400) (author)
منشور في: 2025
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513523585908736
author Lubna Therachiyil (4246156)
author2 Ajaz A. Bhat (12984701)
Shahab Uddin (154400)
author2_role author
author
author_facet Lubna Therachiyil (4246156)
Ajaz A. Bhat (12984701)
Shahab Uddin (154400)
author_role author
dc.creator.none.fl_str_mv Lubna Therachiyil (4246156)
Ajaz A. Bhat (12984701)
Shahab Uddin (154400)
dc.date.none.fl_str_mv 2025-08-13T09:00:00Z
dc.identifier.none.fl_str_mv 10.1080/21688370.2025.2539026
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Claudins_in_ovarian_cancer_emerging_biomarkers_and_therapeutic_targets/31241596
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Oncology and carcinogenesis
Reproductive medicine
Biomarker
Claudins
ovarian cancer
therapeutic target
tight junction
dc.title.none.fl_str_mv Claudins in ovarian cancer: emerging biomarkers and therapeutic targets
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <p dir="ltr">Tight junctions (TJ) comprise protein complexes that help with the movement of ions and molecules through the paracellular pathway, thus maintaining both epithelial and endothelial integrity. The TJ proteins are diverse and include claudins, occludins, tricellulins, cingulins, and junctional adhesion molecules (JAM). Claudins are transmembrane proteins that serve as critical components of TJs in epithelial and endothelial cells. The human genome comprises 23 claudin genes, with 27 transmembrane domains recognized in mammals. Ovarian cancer (OC) is the most lethal form of all gynecologic malignancies worldwide, characterized by poor prognosis and a recurrence rate of up to 75%. In OC, several claudins are overexpressed relative to normal ovarian tissue. These elevated expression observed among OC subtypes indicates their potential utility as diagnostic biomarkers. Claudins represent potential targets for innovative therapeutic strategies. Though their exact involvement in OC is still not well understood, they are believed to be crucial for cancer invasion and therapy resistance. Recent studies show that claudins are involved in the EMT pathway and ERK, enlightening the effect of claudins in drug resistance. Clostridium perfringens enterotoxin (CPE) demonstrates potential as a therapy targeting claudins, specifically claudin-3 and −4, which serve as receptors for this toxin. Despite these advancements, challenges remain in comprehensively understanding claudin functions and in the development of effective claudin-targeted therapies. This review consolidates existing knowledge regarding claudins in OC, focusing on their expression patterns, biological functions, diagnostic and prognostic significance, and therapeutic implications. A thorough understanding of claudins in OC establishes a basis for enhancing diagnostic, predictive, and therapeutic approaches, which may result in improved therapy outcomes.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: Tissue Barriers<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1080/21688370.2025.2539026" target="_blank">https://dx.doi.org/10.1080/21688370.2025.2539026</a></p>
eu_rights_str_mv openAccess
id Manara2_b5769649562890dc11235777797db110
identifier_str_mv 10.1080/21688370.2025.2539026
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/31241596
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Claudins in ovarian cancer: emerging biomarkers and therapeutic targetsLubna Therachiyil (4246156)Ajaz A. Bhat (12984701)Shahab Uddin (154400)Biomedical and clinical sciencesOncology and carcinogenesisReproductive medicineBiomarkerClaudinsovarian cancertherapeutic targettight junction<p dir="ltr">Tight junctions (TJ) comprise protein complexes that help with the movement of ions and molecules through the paracellular pathway, thus maintaining both epithelial and endothelial integrity. The TJ proteins are diverse and include claudins, occludins, tricellulins, cingulins, and junctional adhesion molecules (JAM). Claudins are transmembrane proteins that serve as critical components of TJs in epithelial and endothelial cells. The human genome comprises 23 claudin genes, with 27 transmembrane domains recognized in mammals. Ovarian cancer (OC) is the most lethal form of all gynecologic malignancies worldwide, characterized by poor prognosis and a recurrence rate of up to 75%. In OC, several claudins are overexpressed relative to normal ovarian tissue. These elevated expression observed among OC subtypes indicates their potential utility as diagnostic biomarkers. Claudins represent potential targets for innovative therapeutic strategies. Though their exact involvement in OC is still not well understood, they are believed to be crucial for cancer invasion and therapy resistance. Recent studies show that claudins are involved in the EMT pathway and ERK, enlightening the effect of claudins in drug resistance. Clostridium perfringens enterotoxin (CPE) demonstrates potential as a therapy targeting claudins, specifically claudin-3 and −4, which serve as receptors for this toxin. Despite these advancements, challenges remain in comprehensively understanding claudin functions and in the development of effective claudin-targeted therapies. This review consolidates existing knowledge regarding claudins in OC, focusing on their expression patterns, biological functions, diagnostic and prognostic significance, and therapeutic implications. A thorough understanding of claudins in OC establishes a basis for enhancing diagnostic, predictive, and therapeutic approaches, which may result in improved therapy outcomes.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: Tissue Barriers<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1080/21688370.2025.2539026" target="_blank">https://dx.doi.org/10.1080/21688370.2025.2539026</a></p>2025-08-13T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1080/21688370.2025.2539026https://figshare.com/articles/journal_contribution/Claudins_in_ovarian_cancer_emerging_biomarkers_and_therapeutic_targets/31241596CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/312415962025-08-13T09:00:00Z
spellingShingle Claudins in ovarian cancer: emerging biomarkers and therapeutic targets
Lubna Therachiyil (4246156)
Biomedical and clinical sciences
Oncology and carcinogenesis
Reproductive medicine
Biomarker
Claudins
ovarian cancer
therapeutic target
tight junction
status_str publishedVersion
title Claudins in ovarian cancer: emerging biomarkers and therapeutic targets
title_full Claudins in ovarian cancer: emerging biomarkers and therapeutic targets
title_fullStr Claudins in ovarian cancer: emerging biomarkers and therapeutic targets
title_full_unstemmed Claudins in ovarian cancer: emerging biomarkers and therapeutic targets
title_short Claudins in ovarian cancer: emerging biomarkers and therapeutic targets
title_sort Claudins in ovarian cancer: emerging biomarkers and therapeutic targets
topic Biomedical and clinical sciences
Oncology and carcinogenesis
Reproductive medicine
Biomarker
Claudins
ovarian cancer
therapeutic target
tight junction